Search

Your search keyword '"Eric Piver"' showing total 30 results
Start Over Author "Eric Piver" Language english
30 results on '"Eric Piver"'

1. Inflammatory mediators, lipoproteins and apolipoproteins in early diagnosis of amyotrophic lateral sclerosis

Author

Hugo Alarcan, Mélanie Berthet, Laura Suire, Corentin Colas, Loïc Gonzalez, Christophe Paget, Isabelle Benz-de Bretagne, Eric Piver, Patrick Vourc'h, Christian Andres, Philippe Corcia, and Hélène Blasco

Subjects
Amyotrophic lateral sclerosis, Lipids, Apolipoproteins, Inflammatory mediators, PLS-DA, Biotechnology, TP248.13-248.65, Medical technology, R855-855.5
Abstract

There is currently no diagnostic or prognostic biomarker available in clinical practice for Amyotrophic Lateral Sclerosis (ALS). The objective of this study was to monitor a combination of various inflammatory markers, lipids, and apolipoproteins alterations in ALS patients at the time of diagnosis, to assess their role as early diagnostic or prognostic biomarker candidates. C-reactive protein, orosomucoid, prealbumin, calprotectin, lipids and apoliproteins were determined in the blood of all subjects (25 ALS patients, 23 controls) as routinely performed in our laboratory. Inflammatory mediators were evaluated by a bead-based multiplex assay. A two-step approach was used for each analytical strategy: univariate analysis followed by multivariate analysis. Eight features were significantly different between ALS patients and controls, sometimes with important fold changes. The supervised Partial least Squares Discriminant Analysis separated ALS and controls with great accuracy (94 %) and the permutation test was significant (p < 0.01), ensuring the robustness of the model. The prediction model leads to a mean sensitivity and specificity of 90 (+/- 10) and 78 (+/- 10) %, respectively, with a mean predictive positive value and negative predictive value of 80 (+/- 8.9) and 89 (+/- 11.8) %, respectively. However, the models did not discriminate subgroups of ALS patients based on ALS characteristics. This study highlights the usefulness of evaluating a combination of multiple pathways rather than focusing on a single target. These promising results suggest the need for the longitudinal monitoring of these candidates to determine their role in disease evolution.

Published
2022
Full Text
View/download PDF

2. Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses

Author

Alba Rodríguez-García, Nicolas Mennesson, Gema Hernandez-Ibarburu, María Luz Morales, Laurent Garderet, Lorine Bouchereau, Sophie Allain-Maillet, Eric Piver, Irene Marbán, David Rubio, Edith Bigot-Corbel, Joaquín Martínez-López, María Linares, and Sylvie Hermouet

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Subsets of multiple myeloma (MM) and monoclonal gammopathies of undetermined significance (MGUS) present with a monoclonal immunoglobulin specific for hepatitis C virus (HCV), thus are presumably HCV-driven, and antiviral treatment can lead to the disappearance of antigen stimulation and improved control of clonal plasma cells. Here we studied the role of hepatitis B virus (HBV) in the pathogenesis of MGUS and MM in 45 HBV-infected patients with monoclonal gammopathy. We analyzed the specificity of recognition of the monoclonal immunoglobulin of these patients and validated the efficacy of antiviral treatment (AVT). For 18 of 45 (40%) HBV-infected patients, the target of the monoclonal immunoglobulin was identified: the most frequent target was HBV (n=11), followed by other infectious pathogens (n=6) and glucosylsphingosine (n=1). Two patients whose monoclonal immunoglobulin targeted HBV (HBx and HBcAg), implying that their gammopathy was HBV-driven, received AVT and the gammopathy did not progress. AVT efficacy was then investigated in a large cohort of HBV-infected MM patients (n=1367) who received or did not receive anti-HBV treatments and compared to a cohort of HCV-infected MM patients (n=1220). AVT significantly improved patient probability of overall survival (P=0.016 for the HBV-positive cohort, P=0.005 for the HCV-positive cohort). Altogether, MGUS and MM disease can be HBV- or HCV-driven in infected patients, and the study demonstrates the importance of AVT in such patients.

Published
2023
Full Text
View/download PDF

3. Implication of Central Nervous System Barrier Impairment in Amyotrophic Lateral Sclerosis: Gender-Related Difference in Patients

Author

Hugo Alarcan, Patrick Vourc’h, Lise Berton, Isabelle Benz-De Bretagne, Eric Piver, Christian R. Andres, Philippe Corcia, Charlotte Veyrat-Durebex, and Hélène Blasco

Subjects
amyotrophic lateral sclerosis, QAlb, central nervous system barrier, C9orf72, blood–brain barrier, spinal cord barrier, Biology (General), QH301-705.5, Chemistry, QD1-999
Abstract

Central nervous system (CNS) barrier impairment has been reported in amyotrophic lateral sclerosis (ALS), highlighting its potential significance in the disease. In this context, we aim to shed light on its involvement in the disease, by determining albumin quotient (QAlb) at the time of diagnosis of ALS in a large cohort of patients. Patients from the university hospital of Tours (n = 307) were included in this monocentric, retrospective study. In total, 92 patients (30%) had elevated QAlb levels. This percentage was higher in males (43%) than in females (15%). Interestingly, QAlb was not associated with age of onset, age at sampling or diagnostic delay. However, we found an association with ALS functional rating scale-revised (ALSFRS-r) at diagnosis but this was significant only in males. The QAlb levels were not linked to the presence of a pathogenic mutation. Finally, we performed a multivariate survival analysis and found that QAlb was significantly associated with survival in male patients (HR = 2.3, 95% CI = 1.2–4.3, p = 0.009). A longitudinal evaluation of markers of barrier impairment, in combination with inflammatory biomarkers, could give insight into the involvement of CNS barrier impairment in the pathogenesis of the disease. The gender difference might guide the development of new drugs and help personalise the treatment of ALS.

Published
2023
Full Text
View/download PDF

4. Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients

Author

Adrien Bosseboeuf, Célia Seillier, Nicolas Mennesson, Sophie Allain-Maillet, Maeva Fourny, Anne Tallet, Eric Piver, Philippe Lehours, Francis Mégraud, Laureline Berthelot, Jean Harb, Edith Bigot-Corbel, and Sylvie Hermouet

Subjects
monoclonal immunoglobulin A (IgA), multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), infectious antigens, Epstein–Barr virus, hepatitis C virus, Immunologic diseases. Allergy, RC581-607
Abstract

Previous studies showed that monoclonal immunoglobulins G (IgGs) of “monoclonal gammopathy of undetermined significance” (MGUS) and myeloma were hyposialylated, thus presumably pro-inflammatory, and for about half of patients, the target of the monoclonal IgG was either a virus—Epstein–Barr virus (EBV), other herpes viruses, hepatitis C virus (HCV)—or a glucolipid, lysoglucosylceramide (LGL1), suggesting antigen-driven disease in these patients. In the present study, we show that monoclonal IgAs share these characteristics. We collected 35 sera of patients with a monoclonal IgA (6 MGUS, 29 myeloma), and we were able to purify 25 of the 35 monoclonal IgAs (6 MGUS, 19 myeloma). Monoclonal IgAs from MGUS and myeloma patients were significantly less sialylated than IgAs from healthy volunteers. When purified monoclonal IgAs were tested against infectious pathogens and LGL1, five myeloma patients had a monoclonal IgA that specifically recognized viral proteins: the core protein of HCV in one case, EBV nuclear antigen 1 (EBNA-1) in four cases (21.1% of IgA myeloma). Monoclonal IgAs from three myeloma patients reacted against LGL1. In summary, monoclonal IgAs are hyposialylated and as described for IgG myeloma, significant subsets (8/19, or 42%) of patients with IgA myeloma may have viral or self (LGL1) antigen-driven disease.

Published
2020
Full Text
View/download PDF

5. Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial

Author

Grégoire Cormier, Benoit Le Goff, Emmanuelle Dernis, Philippe Goupille, Aleth Perdriger, Theo Rispens, David Ternant, Gilles Paintaud, Emilie Ducourau, Marine Samain, Fabienne Le Guilchard, Lucia Andras, Eric Lespessailles, Thomas Armingeat, Valérie Devauchelle-Pensec, Elisabeth Gervais, Annick de Vries, Eric Piver, Céline Desvignes, Hervé Watier, and Denis Mulleman

Subjects
Medicine
Abstract

Objectives Anti-drug antibodies (ADA) are responsible for decreased adalimumab efficacy in axial spondyloarthritis (SpA). We aimed to evaluate the ability of methotrexate (MTX) to decrease adalimumab immunisation.Methods A total of 110 patients eligible to receive adalimumab 40 mg subcutaneously (s.c.) every other week were randomised (1:1 ratio) to receive, 2 weeks before adalimumab (W-2) and weekly, MTX 10 mg s.c. (MTX+) or not (MTX−). ADA detection and adalimumab serum concentration were assessed at weeks 4 (W4), 8 (W8), 12 (W12) and 26 (W26) after starting adalimumab (W0). The primary outcome was the proportion of patients with ADA at W26. Four years after the study completion, we retrospectively analysed adalimumab maintenance in relation with MTX co-treatment duration.Results We analysed data for 107 patients (MTX+; n=52; MTX-; n=55). ADA were detected at W26 in 39/107 (36.4%) patients: 13/52 (25%) in the MTX+ group and 26/55 (47.3%) in the MTX− group (p=0.03). Adalimumab concentration was significantly higher in the MTX+ than MTX− group at W4, W8, W12 and W26. The two groups did not differ in adverse events or efficacy. In the follow-up study, MTX co-treatment >W26 versus no MTX or ≤W26 was significantly associated with adalimumab long-term maintenance (p=0.04).Conclusion MTX reduces the immunogenicity and ameliorate the pharmacokinetics of adalimumab in axial SpA. A prolonged co-treatment of MTX>W26 seems to increase adalimumab long-term maintenance.

Published
2020
Full Text
View/download PDF

6. Enhanced Amikacin Diffusion With Ultrasound and Microbubbles in a Mechanically Ventilated Condensed Lung Rabbit Model

Author

Fabien Espitalier, François Darrouzain, Jean-Michel Escoffre, David Ternant, Eric Piver, Ayache Bouakaz, and Francis Remerand

Subjects
sonoporation, ultrasound, microbubbles, antibiotic therapy, lung, amikacin, Therapeutics. Pharmacology, RM1-950
Abstract

The poor diffusion of intravenous antibiotics in lung tissue makes nosocomial pneumonia challenging to treat, notably in critical patients under mechanical ventilation. The combination of ultrasound and microbubbles (USMB) is an emerging method for non-invasive and targeted enhancement of uptake of various drugs in several organs. This study aims to evaluate if USMB may increase amikacin concentration in condensed lung tissues in a mechanically ventilated rabbit model. When applied 60 or 160 min after the beginning of an intravenous amikacin infusion, USMB increased amikacin concentration in the condensed lung tissue by 1.33 (p = 0.025) or 1.56-fold (p = 0.028) respectively. When applied 70 min after the beginning of an intravenous amikacin infusion, USMB increased amikacin concentration in the muscle tissue by 2.52 (p = 0.025). In conclusion, this study demonstrates that USMB is a promising method for the targeted delivery of amikacin in mechanically ventilated condensed lung, thus opening new therapeutic fields against lung infections.

Published
2020
Full Text
View/download PDF

7. Galectin-3 predicts response and outcomes after cardiac resynchronization therapy

Author

Clémentine Andre, Eric Piver, Romain Perault, Arnaud Bisson, Julien Pucheux, Emmanuelle Vermes, Bertrand Pierre, Laurent Fauchier, Dominique Babuty, and Nicolas Clementy

Subjects
Galectin-3, Heart failure, Cardiac resynchronization therapy, Medicine
Abstract

Abstract Background Cardiac resynchronization therapy (CRT) reduces symptoms, morbidity and mortality in chronic heart failure patients with wide QRS complexes. However, approximately one third of CRT patients are non-responders. Myocardial fibrosis is known to be associated with absence of response. We sought to see whether galectin-3, a promising biomarker involved in fibrosis processes, could predict response and outcomes after CRT. Methods Consecutive patients eligible for implantation of a CRT device with a typical left bundle branch block ≥ 120 ms were prospectively included. Serum Gal-3 level, Selvester ECG scoring, and cardiac magnetic resonance with analysis of late gadolinium enhancement (LGE) were ascertained. Response to CRT was defined by a composite endpoint at 6 months: no death, nor hospitalization for major cardiovascular event, and a significant decrease in left ventricular end-systolic volume of 15% or more. Results Sixty-one patients were included (age 61 ± 5 years, ejection fraction 27 ± 5%), 59% with non-ischemic cardiomyopathy. At 6 months, 49 patients (80%) were considered responders. Responders had a lower percentage of LGE (8 ± 13% vs 22 ± 16%, p = 0.006), and a trend towards lower rates of galectin-3 (16 ± 6 ng/mL vs 19 ± 8 ng/mL, p = 0.13). LGE ≥ 14% and Gal-3 ≥ 22 ng/mL independently predicted response to CRT (OR = 0.17 [0.03–0.62], p = 0.007, and OR = 0.11 [0.02–0.04], p

Published
2018
Full Text
View/download PDF

8. Primary solitary plasmacytoma of the liver – successful treatment with fractionated stereotactic radiotherapy (Cyberknife®): a case report

Author

Thomas Chalopin, Isabelle Barillot, Jean-Paul Biny, Flavie Arbion, Marie Besson, Maria Santiago-Ribeiro, Eric Piver, Olivier Herault, Emmanuel Gyan, and Lotfi Benboubker

Subjects
Solitary plasmacytoma, Liver, Radiosurgery, Medicine
Abstract

Abstract Background Solitary plasmacytoma of the liver is a very rare and aggressive form of plasma cell dyscrasia. To the best of our knowledge, very few cases have been reported without systemic disease. We reported a rare case of hepatic solitary plasmacytoma that successfully responded to fractionated stereotactic radiotherapy. Case presentation A 64-year-old white French man had monoclonal gammopathy of the immune globulin G lambda type; he developed a cholestasis and cytolysis with the discovery of a subscapular nodule. A biopsy showed plasma cells and, for several reasons, the decision was made to use the fractionated stereotactic radiotherapy strategy. After 20 months, he is asymptomatic and the immune globulin G component has completely disappeared. Conclusion We suggest considering Cyberknife® radiosurgery as an option for the treatment of hepatic solitary plasmacytoma.

Published
2017
Full Text
View/download PDF

9. SCN4B acts as a metastasis-suppressor gene preventing hyperactivation of cell migration in breast cancer

Author

Emeline Bon, Virginie Driffort, Frédéric Gradek, Carlos Martinez-Caceres, Monique Anchelin, Pablo Pelegrin, Maria-Luisa Cayuela, Séverine Marionneau-Lambot, Thibauld Oullier, Roseline Guibon, Gaëlle Fromont, Jorge L. Gutierrez-Pajares, Isabelle Domingo, Eric Piver, Alain Moreau, Julien Burlaud-Gaillard, Philippe G. Frank, Stéphan Chevalier, Pierre Besson, and Sébastien Roger

Subjects
Science
Abstract

The capacity of cancer cells to migrate is intimately linked to their ability to induce metastasis. Here the authors show that the sodium channel β4 subunit regulates breast cancer cell migration via inhibition of RhoA activation, independently from its function as an auxiliary protein of the sodium channel.

Published
2016
Full Text
View/download PDF

10. Comparison of Monoclonal Gammopathies Linked to Poliovirus or Coxsackievirus vs. Other Infectious Pathogens

Author

Jean Harb, Nicolas Mennesson, Cassandra Lepetit, Maeva Fourny, Margaux Louvois, Adrien Bosseboeuf, Sophie Allain-Maillet, Olivier Decaux, Caroline Moreau, Anne Tallet, Eric Piver, Philippe Moreau, Valéry Salle, Edith Bigot-Corbel, and Sylvie Hermouet

Subjects
poliovirus, coxsackievirus, monoclonal gammopathy, MGUS, multiple myeloma, monoclonal immunoglobulin, Cytology, QH573-671
Abstract

Chronic stimulation by infectious pathogens or self-antigen glucosylsphingosine (GlcSph) can lead to monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). Novel assays such as the multiplex infectious antigen microarray (MIAA) and GlcSph assays, permit identification of targets for >60% purified monoclonal immunoglobulins (Igs). Searching for additional targets, we selected 28 purified monoclonal Igs whose antigen was not represented on the MIAA and GlcSph assays; their specificity of recognition was then analyzed using microarrays consisting of 3760 B-cell epitopes from 196 pathogens. The peptide sequences PALTAVETG and PALTAAETG of the VP1 coat proteins of human poliovirus 1/3 and coxsackievirus B1/B3, respectively, were specifically recognized by 6/28 monoclonal Igs. Re-analysis of patient cohorts showed that purified monoclonal Igs from 10/155 MGUS/SM (6.5%) and 3/147 MM (2.0%) bound to the PALTAVETG or PALTAAETG epitopes. Altogether, PALTAV/AETG-initiated MGUS are not rare and few seem to evolve toward myeloma.

Published
2021
Full Text
View/download PDF

11. The Role of Phosphatidylinositol Phosphate Kinases during Viral Infection

Author

Anne Beziau, Denys Brand, and Eric Piver

Subjects
phosphatidylinositol (PI), phosphatidylinositol phosphate kinases (PIPK), phosphatases, viral replication, Microbiology, QR1-502
Abstract

Phosphoinositides account for only a small proportion of cellular phospholipids, but have long been known to play an important role in diverse cellular processes, such as cell signaling, the establishment of organelle identity, and the regulation of cytoskeleton and membrane dynamics. As expected, given their pleiotropic regulatory functions, they have key functions in viral replication. The spatial restriction and steady-state levels of each phosphoinositide depend primarily on the concerted action of specific phosphoinositide kinases and phosphatases. This review focuses on a number of remarkable examples of viral strategies involving phosphoinositide kinases to ensure effective viral replication.

Published
2020
Full Text
View/download PDF

12. Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure.

Author

Nicolas Clementy, Bruno Garcia, Clémentine André, Arnaud Bisson, Nazih Benhenda, Bertrand Pierre, Anne Bernard, Laurent Fauchier, Eric Piver, and Dominique Babuty

Subjects
Medicine, Science
Abstract

INTRODUCTION:Mechanisms of maintenance of both atrial fibrillation and structural left ventricular disease are known to include fibrosis. Galectin-3, a biomarker of fibrosis, is elevated both in patients with heart failure and persistent atrial fibrillation. We sought to find whether galectin-3 has a prognostic value in patients with heart failure and a reduced left ventricular ejection fraction undergoing ablation of persistent atrial fibrillation. METHODS:Serum concentrations of galectin-3 were determined in a consecutive series of patients with an ejection fraction ≤40%, addressed for ablation of persistent atrial fibrillation. Responders to ablation were patients in sinus rhythm and with an ejection fraction ≥50% at 6 months. A combined endpoint of heart failure hospitalization, transplantation and/or death was used at 12 months. RESULTS:Seventy-five patients were included (81% male, age 63±10 years, ejection fraction 34±7%, galectin-3 21±12 ng/mL). During follow-up, eight patients were hospitalized for decompensated heart failure, 1 underwent heart transplantation, and 4 died; 50 patients were considered as responders to ablation. After adjustment, galectin-3 level independently predicted both 6-month absence of response to ablation (OR = 0.89 per unit increase, p = 0.002). Patients with galectin-3 levels

Published
2018
Full Text
View/download PDF

13. Pro-inflammatory State in Monoclonal Gammopathy of Undetermined Significance and in Multiple Myeloma Is Characterized by Low Sialylation of Pathogen-Specific and Other Monoclonal Immunoglobulins

Author

Adrien Bosseboeuf, Sophie Allain-Maillet, Nicolas Mennesson, Anne Tallet, Cédric Rossi, Laurent Garderet, Denis Caillot, Philippe Moreau, Eric Piver, François Girodon, Hélène Perreault, Sophie Brouard, Arnaud Nicot, Edith Bigot-Corbel, Sylvie Hermouet, and Jean Harb

Subjects
myeloma, monoclonal gammopathy of undetermined significance, monoclonal immunoglobulin, immunoglobulin G sialylation, infection, inflammation, Immunologic diseases. Allergy, RC581-607
Abstract

Multiple myeloma (MM) and its pre-cancerous stage monoclonal gammopathy of undetermined significance (MGUS) allow to study immune responses and the chronology of inflammation in the context of blood malignancies. Both diseases are characterized by the production of a monoclonal immunoglobulin (mc Ig) which for subsets of MGUS and MM patients targets pathogens known to cause latent infection, a major cause of inflammation. Inflammation may influence the structure of both polyclonal (pc) Ig and mc Ig produced by malignant plasma cells via the sialylation of Ig Fc fragment. Here, we characterized the sialylation of purified mc and pc IgGs from 148 MGUS and MM patients, in comparison to pc IgGs from 46 healthy volunteers. The inflammatory state of patients was assessed by the quantification in serum of 40 inflammation-linked cytokines, using Luminex technology. While pc IgGs from MGUS and MM patients showed heterogeneity in sialylation level, mc IgGs from both MGUS and MM patients exhibited a very low level of sialylation. Furthermore, mc IgGs from MM patients were less sialylated than mc IgGs from MGUS patients (p

Published
2017
Full Text
View/download PDF

14. Galectin-3 in Atrial Fibrillation: Mechanisms and Therapeutic Implications

Author

Nicolas Clementy, Eric Piver, Arnaud Bisson, Clémentine Andre, Anne Bernard, Bertrand Pierre, Laurent Fauchier, and Dominique Babuty

Subjects
galectin-3, atrial fibrillation, ablation, Biology (General), QH301-705.5, Chemistry, QD1-999
Abstract

Maintenance of atrial fibrillation is a complex mechanism, including extensive electrical and structural remodeling of the atria which involves progressive fibrogenesis. Galectin-3 is a biomarker of fibrosis, and, thus, may be involved in atrial remodeling in atrial fibrillation patients. We review the role of galectin-3 in AF mechanisms and its potential therapeutic implications.

Published
2018
Full Text
View/download PDF

15. Highly efficient in vitro and in vivo delivery of functional RNAs using new versatile MS2-chimeric retrovirus-like particles

Author

Anne Prel, Vincent Caval, Régis Gayon, Philippe Ravassard, Christine Duthoit, Emmanuel Payen, Leila Maouche-Chretien, Alison Creneguy, Tuan Huy Nguyen, Nicolas Martin, Eric Piver, Raphaël Sevrain, Lucille Lamouroux, Philippe Leboulch, Frédéric Deschaseaux, Pascale Bouillé, Luc Sensébé, and Jean-Christophe Pagès

Subjects
Genetics, QH426-470, Cytology, QH573-671
Abstract

RNA delivery is an attractive strategy to achieve transient gene expression in research projects and in cell- or gene-based therapies. Despite significant efforts investigating vector-directed RNA transfer, there is still a requirement for better efficiency of delivery to primary cells and in vivo. Retroviral platforms drive RNA delivery, yet retrovirus RNA-packaging constraints limit gene transfer to two genome-molecules per viral particle. To improve retroviral transfer, we designed a dimerization-independent MS2-driven RNA packaging system using MS2-Coat-retrovirus chimeras. The engineered chimeric particles promoted effective packaging of several types of RNAs and enabled efficient transfer of biologically active RNAs in various cell types, including human CD34+ and iPS cells. Systemic injection of high-titer particles led to gene expression in mouse liver and transferring Cre-recombinase mRNA in muscle permitted widespread editing at the ROSA26 locus. We could further show that the VLPs were able to activate an osteoblast differentiation pathway by delivering RUNX2- or DLX5-mRNA into primary human bone-marrow mesenchymal-stem cells. Thus, the novel chimeric MS2-lentiviral particles are a versatile tool for a wide range of applications including cellular-programming or genome-editing.

Published
2015
Full Text
View/download PDF

16. Viral sequence variation in chronic carriers of hepatitis C virus has a low impact on liver steatosis.

Author

Marion Depla, Louis d'Alteroche, Amélie Le Gouge, Alain Moreau, Christophe Hourioux, Jean-Christophe Meunier, Julien Gaillard, Anne de Muret, Yannick Bacq, Farhad Kazemi, Aurélie Avargues, Emmanuelle Roch, Eric Piver, Catherine Gaudy-Graffin, Bruno Giraudeau, and Philippe Roingeard

Subjects
Medicine, Science
Abstract

Most clinical studies suggest that the prevalence and severity of liver steatosis are higher in patients infected with hepatitis C virus (HCV) genotype 3 than in patients infected with other genotypes. This may reflect the diversity and specific intrinsic properties of genotype 3 virus proteins. We analyzed the possible association of particular residues of the HCV core and NS5A proteins known to dysregulate lipid metabolism with steatosis severity in the livers of patients chronically infected with HCV. We used transmission electron microscopy to quantify liver steatosis precisely in a group of 27 patients, 12 of whom were infected with a genotype 3 virus, the other 15 being infected with viruses of other genotypes. We determined the area covered by lipid droplets in liver tissues and analyzed the diversity of the core and NS5A regions encoded by the viral variants circulating in these patients. The area covered by lipid droplets did not differ significantly between patients infected with genotype 3 viruses and those infected with other genotypes. The core and NS5A protein sequences of the viral variants circulating in patients with mild or severe steatosis were evenly distributed throughout the phylogenic trees established from all the collected sequences. Thus, individual host factors seem to play a much greater role than viral factors in the development of severe steatosis in patients chronically infected with HCV, including those infected with genotype 3 viruses.

Published
2012
Full Text
View/download PDF

17. Implication of Central Nervous System Barrier Impairment in Amyotrophic Lateral Sclerosis: Gender-Related Difference in Patients

Author

Blasco, Hugo Alarcan, Patrick Vourc’h, Lise Berton, Isabelle Benz-De Bretagne, Eric Piver, Christian R. Andres, Philippe Corcia, Charlotte Veyrat-Durebex, and Hélène

Subjects
amyotrophic lateral sclerosis, QAlb, central nervous system barrier, C9orf72, blood–brain barrier, spinal cord barrier
Abstract

Central nervous system (CNS) barrier impairment has been reported in amyotrophic lateral sclerosis (ALS), highlighting its potential significance in the disease. In this context, we aim to shed light on its involvement in the disease, by determining albumin quotient (QAlb) at the time of diagnosis of ALS in a large cohort of patients. Patients from the university hospital of Tours (n = 307) were included in this monocentric, retrospective study. In total, 92 patients (30%) had elevated QAlb levels. This percentage was higher in males (43%) than in females (15%). Interestingly, QAlb was not associated with age of onset, age at sampling or diagnostic delay. However, we found an association with ALS functional rating scale-revised (ALSFRS-r) at diagnosis but this was significant only in males. The QAlb levels were not linked to the presence of a pathogenic mutation. Finally, we performed a multivariate survival analysis and found that QAlb was significantly associated with survival in male patients (HR = 2.3, 95% CI = 1.2–4.3, p = 0.009). A longitudinal evaluation of markers of barrier impairment, in combination with inflammatory biomarkers, could give insight into the involvement of CNS barrier impairment in the pathogenesis of the disease. The gender difference might guide the development of new drugs and help personalise the treatment of ALS.

Published
2023
Full Text
View/download PDF

18. Salivary metabolome indicates a shift in tyrosine metabolism in patients with burning mouth syndrome: a prospective case–control study

Author

Charlotte Moreau, Chakib El Habnouni, Jean-Claude Lecron, Franck Morel, Adriana Delwail, Christelle Le Gall-Ianotto, Raphaele Le Garrec, Laurent Misery, Eric Piver, Loïc Vaillant, Antoine Lefevre, Patrick Emond, Hélène Blasco, Mahtab Samimi, Université de Tours (UT), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Service Immunologie/Inflammation [CHU Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Laboratoire Inflammation, Tissus épithéliaux et Cytokines (LITEC), Université de Poitiers, ImageUP (Plateforme d'Imagerie de l'Université de Poitiers), Signalisation et Transports Ioniques Membranaires (STIM), Université de Poitiers-Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS), Laboratoire sur les interactions Epithéliums Neurones (LIEN), Université de Brest (UBO), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Médecine Nucléaire [Tours], CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Infectiologie et Santé Publique (UMR ISP), Université de Tours (UT)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and Chanteloup, Nathalie Katy

Subjects
Anesthesiology and Pain Medicine, Neurology, Neurology (clinical), [SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract

International audience; The pathophysiology of primary burning mouth syndrome (BMS) remains controversial. Targeted analyses or "omics" approach of saliva provide diagnostic or pathophysiological biomarkers. This pilot study's primary objective was to explore the pathophysiology of BMS through a comparative analysis of the salivary metabolome among 26 BMS female cases and 25 age- and sex-matched control subjects. Secondary objectives included comparative analyses of inflammatory cytokines, neuroinflammatory markers, and steroid hormones among cases and control subjects, and among BMS patients according to their clinical characteristics. Salivary metabolome, neuroinflammatory markers, cytokines, and steroids were, respectively, analysed by liquid chromatography coupled with mass spectrometry, ELISA and protease activity assay, and multiparametric Luminex method. Among the 166 detected metabolites, univariate analysis did not find any discriminant metabolite between groups. Supervised multivariate analysis divided patients into 2 groups with an accuracy of 60% but did not allow significant discrimination (permutation test, P = 0.35). Among the metabolites contributing to the model, 3 belonging to the tyrosine pathway ( l -dopa, l -tyrosine, and tyramine) were involved in the discrimination between cases and control subjects, and among BMS patients according to their levels of pain. Among the detectable molecules, levels of cytokines, steroid hormones, and neuroinflammatory markers did not differ between cases and control subjects and were not associated with characteristics of BMS patients. These results do not support the involvement of steroid hormones, inflammatory cytokines, or inflammatory neurogenic mediators in the pathophysiology of pain in BMS, whereas the observed shift in tyrosine metabolism may indicate an adaptative response to chronic pain or an impaired dopaminergic transmission.

Published
2022

19. Comparison of Monoclonal Gammopathies Linked to Poliovirus or Coxsackievirus vs. Other Infectious Pathogens

Author

Adrien Bosseboeuf, Philippe Moreau, Caroline Moreau, Olivier Decaux, Valéry Salle, Anne Tallet, Margaux Louvois, Cassandra Lepetit, Sylvie Hermouet, Maeva Fourny, Nicolas Mennesson, Edith Bigot-Corbel, Jean Harb, Sophie Allain-Maillet, Eric Piver, Molecular Mechanisms of Chronic Inflammation in Hematological Diseases (CRCINA-ÉQUIPE 16), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Université de Nantes (UN)-Université de Nantes (UN), Laboratoire de Biochimie [Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Service de Médecine interne et immunologie clinique [Rennes] = internal medicine and clinical immunology [Rennes], CHU Pontchaillou [Rennes], Laboratoire de Biochimie [Rennes], Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Laboratoire de Biochimie [CHRU Tours], Morphogénèse et antigénicité du VIH et du virus des Hépatites (MAVIVH - U1259 Inserm - CHRU Tours ), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours, Service d'Hématologie [Nantes], CHU Amiens-Picardie, Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Bernardo, Elizabeth

Subjects
0301 basic medicine, Adult, Microarray, Paraproteinemias, Coxsackievirus Infections, [SDV.CAN]Life Sciences [q-bio]/Cancer, Biology, Coxsackievirus, medicine.disease_cause, Epitope, Article, 03 medical and health sciences, 0302 clinical medicine, Antigen, [SDV.CAN] Life Sciences [q-bio]/Cancer, hemic and lymphatic diseases, medicine, Humans, Multiplex, lcsh:QH301-705.5, Aged, Retrospective Studies, Aged, 80 and over, coxsackievirus, poliovirus, monoclonal immunoglobulin, Poliovirus, monoclonal gammopathy, General Medicine, MGUS, multiple myeloma, infection, pathogen, antigen specificity, Middle Aged, medicine.disease, biology.organism_classification, Virology, 3. Good health, 030104 developmental biology, lcsh:Biology (General), 030220 oncology & carcinogenesis, Monoclonal, Monoclonal gammopathy of undetermined significance
Abstract

International audience; Chronic stimulation by infectious pathogens or self-antigen glucosylsphingosine (GlcSph) can lead to monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). Novel assays such as the multiplex infectious antigen microarray (MIAA) and GlcSph assays, permit identification of targets for >60% purified monoclonal immunoglobulins (Igs). Searching for additional targets, we selected 28 purified monoclonal Igs whose antigen was not represented on the MIAA and GlcSph assays; their specificity of recognition was then analyzed using microarrays consisting of 3760 B-cell epitopes from 196 pathogens. The peptide sequences PALTAVETG and PALTAAETG of the VP1 coat proteins of human poliovirus 1/3 and coxsackievirus B1/B3, respectively, were specifically recognized by 6/28 monoclonal Igs. Re-analysis of patient cohorts showed that purified monoclonal Igs from 10/155 MGUS/SM (6.5%) and 3/147 MM (2.0%) bound to the PALTAVETG or PALTAAETG epitopes. Altogether, PALTAV/AETG-initiated MGUS are not rare and few seem to evolve toward myeloma.

Published
2021

20. Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis

Author

Eric Piver, Grégoire Cormier, Eric Lespessailles, Céline Desvignes, Elisabeth Gervais, Emmanuelle Dernis, Marine Samain, Hervé Watier, Antoine Martin, Gilles Paintaud, Valérie Devauchelle-Pensec, Theo Rispens, Denis Mulleman, Annick de Vries, Emilie Ducourau, Thomas Armingeat, Lucia Andras, Benoit Le Goff, Aleth Perdriger, Fabienne Le Guilchard, Philippe Goupille, David Ternant, Service de rhumatologie [Tours], CHU Trousseau [APHP], Sanquin Research and Landsteiner Laboratory [Amsterdam, The Netherlands], Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA)-University of Amsterdam [Amsterdam] (UvA)-Department of Immunopathology [Amsterdam, The Netherlands], University of Amsterdam [Amsterdam] (UvA), Service de Rhumatologie - CH Le Mans, Centre Hospitalier Le Mans (CH Le Mans), CHR de Blois, Service de Rhumatologie, Service de Rhumatologie, Rennes, Centre Hospitalier Universitaire [Rennes], Imagerie Multimodale Multiéchelle et Modélisation du Tissu Osseux et articulaire (I3MTO), Université d'Orléans (UO), Service de Rhumatologie [Orléans], Centre Hospitalier Régional d'Orléans (CHR), Service de Rhumatologie, CH Saint-Brieuc, Centre hospitalier Saint-Brieuc, Centre Hospitalier Départemental Vendée, CH de Saint-Nazaire, Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Service de rhumatologie [Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service de rhumatologie [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Morphogénèse et antigénicité du VIH et du virus des Hépatites (MAVIVH - U1259 Inserm - CHRU Tours), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Laboratoire de Pharmacologie-Toxicologie [CHRU Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Département de Pharmacologie Médicale [CHRU Tours], Laboratory of Immunology, CHRU de Tours, Tours, France, Service de Médecine Nucléaire, CHRU de Tours, boulevard Tonnellé, 37000 Tours, France, INSERM U930, Université François Rabelais, boulevard Tonnellé, 37000 Tours, France, INSERM CIC 1415, boulevard Tonnellé, 37000 Tours, France., Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Rhumatologie [CH Le Mans], Service de rhumatologie [Rennes] = Rheumatology [Rennes], CHU Pontchaillou [Rennes], Centre Hospitalier Régional d'Orléans (CHRO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Morphogénèse et antigénicité du VIH et du virus des Hépatites (MAVIVH - U1259 Inserm - CHRU Tours ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Lymphocytes B, Autoimmunité et Immunothérapies (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-LabEX IGO Immunothérapie Grand Ouest-Institut Brestois Santé Agro Matière (IBSAM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Landsteiner Laboratory, and AII - Inflammatory diseases

Subjects
Male, [SDV]Life Sciences [q-bio], lcsh:Medicine, Kaplan-Meier Estimate, Gastroenterology, Arthritis, Rheumatoid, 0302 clinical medicine, Every other week, immune system diseases, Immunology and Allergy, heterocyclic compounds, Prospective Studies, Axial spondyloarthritis, skin and connective tissue diseases, ComputingMilieux_MISCELLANEOUS, 0303 health sciences, Immunogenicity, Long term maintenance, Middle Aged, spondyloarthritis, humanities, 3. Good health, Treatment Outcome, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Antirheumatic Agents, [SDV.IMM]Life Sciences [q-bio]/Immunology, Drug Therapy, Combination, Female, medicine.drug, Adult, musculoskeletal diseases, medicine.medical_specialty, Adolescent, Immunology, methotrexate, Maintenance Chemotherapy, Young Adult, 03 medical and health sciences, Rheumatology, Pharmacokinetics, Internal medicine, Spondylarthritis, Adalimumab, medicine, Humans, Adverse effect, Aged, 030304 developmental biology, 030203 arthritis & rheumatology, business.industry, lcsh:R, anti-TNF, Methotrexate, business
Abstract

ObjectivesAnti-drug antibodies (ADA) are responsible for decreased adalimumab efficacy in axial spondyloarthritis (SpA). We aimed to evaluate the ability of methotrexate (MTX) to decrease adalimumab immunisation.MethodsA total of 110 patients eligible to receive adalimumab 40 mg subcutaneously (s.c.) every other week were randomised (1:1 ratio) to receive, 2 weeks before adalimumab (W-2) and weekly, MTX 10 mg s.c. (MTX+) or not (MTX−). ADA detection and adalimumab serum concentration were assessed at weeks 4 (W4), 8 (W8), 12 (W12) and 26 (W26) after starting adalimumab (W0). The primary outcome was the proportion of patients with ADA at W26. Four years after the study completion, we retrospectively analysed adalimumab maintenance in relation with MTX co-treatment duration.ResultsWe analysed data for 107 patients (MTX+; n=52; MTX-; n=55). ADA were detected at W26 in 39/107 (36.4%) patients: 13/52 (25%) in the MTX+ group and 26/55 (47.3%) in the MTX− group (p=0.03). Adalimumab concentration was significantly higher in the MTX+ than MTX− group at W4, W8, W12 and W26. The two groups did not differ in adverse events or efficacy. In the follow-up study, MTX co-treatment >W26 versus no MTX or ≤W26 was significantly associated with adalimumab long-term maintenance (p=0.04).ConclusionMTX reduces the immunogenicity and ameliorate the pharmacokinetics of adalimumab in axial SpA. A prolonged co-treatment of MTX>W26 seems to increase adalimumab long-term maintenance.

Published
2020

21. Type I phosphatidylinositol-4-phosphate 5-kinase α and γ play a key role in targeting HIV-1 Pr55 Gag to the plasma membrane

Author

Antoine Lefebvre, Eric Piver, Sandra Krull, Hugues de Rocquigny, Stephanie Durand, Baptiste Gonzales, Julien Burlaud-Gaillard, Denys Brand, Patrick Emond, Anne Beziau, Morphogénèse et antigénicité du VIH et du virus des Hépatites (MAVIVH - U1259 Inserm - CHRU Tours ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours (UT), Max Delbrueck Center for Molecular Medicine [Berlin, Germany] (MDCMM), Piver, Eric, Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), and Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Gene isoform, Small interfering RNA, Phosphatidylinositol 4-phosphate, Endosome, Immunology, Biology, [SDV.BC.IC] Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB], Microbiology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Virology, Lysosome, [SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB], medicine, 030304 developmental biology, Myristoylation, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, 0303 health sciences, Kinase, Cell biology, medicine.anatomical_structure, chemistry, Insect Science, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, 030217 neurology & neurosurgery, Intracellular
Abstract

HIV-1 assembly occurs principally at the plasma membrane (PM) of infected cells. Gag polyprotein precursors (Pr55Gag) are targeted to the PM, and their binding is mediated by the interaction of myristoylated matrix domain and a PM-specific phosphoinositide, the phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2]. The major synthesis pathway of PI(4,5)P2 involves the activity of phosphatidylinositol-4-phosphate 5-kinase family type 1 composed of three isoforms (PIP5K1α, PIP5K1β, and PIP5K1γ). To examine whether the activity of a specific PIP5K1 isoform determines proper Pr55Gag localization at the PM, we compared the cellular behavior of Pr55Gag in the context of PIP5K1 inhibition using siRNAs that individually targeted each of the three isoforms in TZM-bl HeLa cells. We found that downregulation of PIP5K1α and PIP5K1γ strongly impaired the targeting of Pr55Gag to the PM with a rerouting of the polyprotein within intracellular compartments. The efficiency of Pr55Gag release was thus impaired through the silencing of these two isoforms, while PIP5K1β is dispensable for Pr55Gag targeting to the PM. The PM mistargeting due to the silencing of PIP5K1α leads to Pr55Gag hydrolysis through lysosome and proteasome pathways, while the silencing of PIP5K1γ leads to Pr55Gag accumulation in late endosomes. Our findings demonstrated that, within the PIP5K1 family, only the PI(4,5)P2 pools produced by PIP5K1α and PIP5K1γ are involved in the Pr55Gag PM targeting process.IMPORTANCE PM specificity of Pr55Gag membrane binding is mediated through the interaction of PI(4,5)P2 with the matrix (MA) basic residues. It was shown that overexpression of a PI(4,5)P2-depleting enzyme strongly impaired PM localization of Pr55Gag However, cellular factors that control PI(4,5)P2 production required for Pr55Gag-PM targeting have not yet been characterized. In this study, by individually inhibiting PIP5K1 isoforms, we elucidated a correlation between PI(4,5)P2 metabolism pathways mediated by PIP5K1 isoforms and the targeting of Pr55Gag to the PM of TZM-bl HeLa cells. Confocal microscopy analyses of cells depleted from PIP5K1α and PIP5K1γ show a rerouting of Pr55Gag to various intracellular compartments. Notably, Pr55Gag is degraded by the proteasome and/or by the lysosomes in PIP5K1α-depleted cells, while Pr55Gag is targeted to endosomal vesicles in PIP5K1γ-depleted cells. Thus, our results highlight, for the first time, the roles of PIP5K1α and PIP5K1γ as determinants of Pr55Gag targeting to the PM.

Published
2020

22. Primary solitary plasmacytoma of the liver – successful treatment with fractionated stereotactic radiotherapy (Cyberknife®): a case report

Author

Emmanuel Gyan, Thomas Chalopin, Jean-Paul Biny, Lotfi Benboubker, Flavie Arbion, Olivier Herault, Marie Besson, Eric Piver, Maria Santiago-Ribeiro, and Isabelle Barillot

Subjects
Male, Systemic disease, Pathology, medicine.medical_specialty, medicine.medical_treatment, Plasma cell dyscrasia, Solitary plasmacytoma, lcsh:Medicine, Case Report, Radiosurgery, 03 medical and health sciences, 0302 clinical medicine, Cholestasis, Surgical oncology, Cyberknife, Positron Emission Tomography Computed Tomography, Biopsy, medicine, Humans, Ultrasonography, biology, medicine.diagnostic_test, business.industry, Liver Neoplasms, lcsh:R, General Medicine, Middle Aged, medicine.disease, Magnetic Resonance Imaging, Treatment Outcome, Liver, 030220 oncology & carcinogenesis, biology.protein, Antibody, business, 030217 neurology & neurosurgery, Plasmacytoma
Abstract

Background Solitary plasmacytoma of the liver is a very rare and aggressive form of plasma cell dyscrasia. To the best of our knowledge, very few cases have been reported without systemic disease. We reported a rare case of hepatic solitary plasmacytoma that successfully responded to fractionated stereotactic radiotherapy. Case presentation A 64-year-old white French man had monoclonal gammopathy of the immune globulin G lambda type; he developed a cholestasis and cytolysis with the discovery of a subscapular nodule. A biopsy showed plasma cells and, for several reasons, the decision was made to use the fractionated stereotactic radiotherapy strategy. After 20 months, he is asymptomatic and the immune globulin G component has completely disappeared. Conclusion We suggest considering Cyberknife® radiosurgery as an option for the treatment of hepatic solitary plasmacytoma.

Published
2017

23. Prééclampsie : faut-il intégrer dans la pratique courante les biomarqueurs de dépistage et de pronostic ?

Author

Jean Guibourdenche, Safouane M. Hamdi, Annelise Genoux, Damien Masson, Eric Piver, Corinne Sault, Groupe de recherche en fertilité humaine ( GRFH), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, and CHU Toulouse [Toulouse]

Subjects
Gynecology, 03 medical and health sciences, medicine.medical_specialty, 030219 obstetrics & reproductive medicine, 0302 clinical medicine, business.industry, [SDV]Life Sciences [q-bio], MEDLINE, Medicine, General Medicine, 030204 cardiovascular system & hematology, business
Published
2019

24. Galectin-3 in Atrial Fibrillation: Mechanisms and Therapeutic Implications

Author

Arnaud Bisson, Clémentine André, Nicolas Clementy, Bertrand Pierre, Laurent Fauchier, Dominique Babuty, Eric Piver, Anne Bernard, CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Laboratoire de Biochimie [CHRU Tours], Morphogénèse et antigénicité du VIH et du virus des Hépatites (MAVIVH - U1259 Inserm - CHRU Tours ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Éducation Éthique Santé EA 7505 (EES), Université de Tours (UT), IHU-LIRYC, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux], Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Griset SA, Diehl - Griset, Service de Cardiologie B, Service de Cardiologie (CHU Trousseau, Tours), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-CHU Trousseau [APHP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
0301 basic medicine, medicine.medical_specialty, Galectin 3, Review, 030204 cardiovascular system & hematology, Structural remodeling, ablation, Catalysis, [SHS]Humanities and Social Sciences, Inorganic Chemistry, lcsh:Chemistry, 03 medical and health sciences, 0302 clinical medicine, Hormone Antagonists, Fibrosis, Internal medicine, galectin-3, Atrial Fibrillation, medicine, Animals, Humans, cardiovascular diseases, Physical and Theoretical Chemistry, Enzyme Inhibitors, Molecular Biology, lcsh:QH301-705.5, Spectroscopy, ComputingMilieux_MISCELLANEOUS, Mechanism (biology), business.industry, Organic Chemistry, Atrial fibrillation, General Medicine, Atrial Remodeling, medicine.disease, Computer Science Applications, 030104 developmental biology, lcsh:Biology (General), lcsh:QD1-999, Galectin-3, Models, Animal, Cardiology, cardiovascular system, Biomarker (medicine), business, Biomarkers
Abstract

Maintenance of atrial fibrillation is a complex mechanism, including extensive electrical and structural remodeling of the atria which involves progressive fibrogenesis. Galectin-3 is a biomarker of fibrosis, and, thus, may be involved in atrial remodeling in atrial fibrillation patients. We review the role of galectin-3 in AF mechanisms and its potential therapeutic implications.

Published
2018

25. First Trimester Uterine Artery Doppler, sFlt-1 and PlGF to Predict Preeclampsia in a High-Risk Population

Author

Martine Maréchaud, Franck Perrotin, Florence Eboue, Claudine Le Vaillant, Amélie Le Gouge, Caroline Diguisto, Eric Piver, Valérie Goua, Bruno Giraudeau, MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), and Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques

Subjects
[SDV]Life Sciences [q-bio], 030204 cardiovascular system & hematology, 0302 clinical medicine, Pre-Eclampsia, Pregnancy, Prenatal, Prospective Studies, Uterine artery, Prospective cohort study, Angiogenic markers, reproductive and urinary physiology, Ultrasonography, education.field_of_study, 030219 obstetrics & reproductive medicine, predict, Obstetrics, Maternal Serum Screening Tests, Doppler, Obstetrics and Gynecology, female genital diseases and pregnancy complications, 3. Good health, Uterine Artery, Predictive value of tests, embryonic structures, Gestation, Female, Pregnancy Trimesters, Adult, medicine.medical_specialty, Population, Ultrasonography, Prenatal, Preeclampsia, 03 medical and health sciences, Predictive Value of Tests, medicine.artery, medicine, Humans, pulsatility index, education, Placenta Growth Factor, Gynecology, Vascular Endothelial Growth Factor Receptor-1, business.industry, screening, Case-control study, Ultrasonography, Doppler, medicine.disease, Pregnancy Trimester, First, ROC Curve, Case-Control Studies, severe preeclampsia, Pediatrics, Perinatology and Child Health, business, Biomarkers
Abstract

International audience; OBJECTIVE: The study aims to evaluate the accuracy of combining uterine artery Doppler (UAD), PlGF and sFlt-1 in the first trimester for preeclampsia screening. METHODS: Prospectively enrolled women at high risk of preeclampsia were included. Transabdominal UAD measurements and serum biomarkers were collected between 11 and 13 weeks of gestation in three university hospitals and in one general hospital. The main outcome was preeclampsia. UAD parameters and biomarker levels among women with preeclampsia were compared with those of women in the unaffected group in univariate and multivariate analyses. RESULTS: Out of 226 women included from May 2007 to January 2011, 27 (11.9%) women developed preeclampsia. Among women affected by preeclampsia, the lowest pulsatility index was higher (p\,=\,0.02), bilateral notching was more frequent (p\,=\,0.01), and PlGF was lower (p\

Published
2017

26. SCN4B acts as a metastasis-suppressor gene preventing hyperactivation of cell migration in breast cancer

Author

Gaëlle Fromont, Pierre Besson, Isabelle Domingo, Maria-Luisa Cayuela, Monique Anchelin, Pablo Pelegrín, Alain Moreau, Stephan Chevalier, Eric Piver, Sébastien Roger, Carlos Martinez-Caceres, Thibauld Oullier, Jorge L. Gutierrez-Pajares, Philippe G. Frank, Julien Burlaud-Gaillard, Emeline Bon, Séverine Marionneau-Lambot, Frédéric Gradek, Virginie Driffort, Roseline Guibon, Nutrition, croissance et cancer (U 1069) (N2C), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Liver Unit, Clínica Universitaria, CIBER-EHD, Hospital Virgen de la Arrixaca, Universidad de Murcia, Cancéropôle Grand-Ouest [Bretagne-Centre-Pays de Loire], Cellules Dendritiques, Immunomodulation et Greffes [Tours] (UFR de Médecine - EA4245), Université Francois Rabelais [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Morphogénèse et antigénicité du VIH et du virus des Hépatites (MAVIVH - U1259 Inserm - CHRU Tours ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire Biologie Cellulaire et Microscopie Electronique, Faculté Médecine, EA4245 - Transplantation, Immunologie, Inflammation [Tours] (T2i), Université de Tours (UT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours, Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), and Université de Tours

Subjects
0301 basic medicine, RHOA, Science, General Physics and Astronomy, Down-Regulation, Mice, Nude, Breast Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, Biology, General Biochemistry, Genetics and Molecular Biology, Sodium Channels, Article, 03 medical and health sciences, Cell Movement, Cell Line, Tumor, Human Umbilical Vein Endothelial Cells, Animals, Humans, Genes, Tumor Suppressor, Neoplasm Invasiveness, Neoplasm Metastasis, Zebrafish, Cell Proliferation, Regulation of gene expression, Multidisciplinary, Voltage-Gated Sodium Channel beta-4 Subunit, Cell growth, Cell migration, Epithelial Cells, General Chemistry, Prognosis, Extracellular Matrix, Gene Expression Regulation, Neoplastic, Metastasis Suppressor Gene, Protein Subunits, 030104 developmental biology, Cell culture, Cancer cell, biology.protein, Cancer research, Disease Progression, Female, rhoA GTP-Binding Protein, Ion Channel Gating, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Intracellular
Abstract

The development of metastases largely relies on the capacity of cancer cells to invade extracellular matrices (ECM) using two invasion modes termed ‘mesenchymal' and ‘amoeboid', with possible transitions between these modes. Here we show that the SCN4B gene, encoding for the β4 protein, initially characterized as an auxiliary subunit of voltage-gated sodium channels (NaV) in excitable tissues, is expressed in normal epithelial cells and that reduced β4 protein levels in breast cancer biopsies correlate with high-grade primary and metastatic tumours. In cancer cells, reducing β4 expression increases RhoA activity, potentiates cell migration and invasiveness, primary tumour growth and metastatic spreading, by promoting the acquisition of an amoeboid–mesenchymal hybrid phenotype. This hyperactivated migration is independent of NaV and is prevented by overexpression of the intracellular C-terminus of β4. Conversely, SCN4B overexpression reduces cancer cell invasiveness and tumour progression, indicating that SCN4B/β4 represents a metastasis-suppressor gene., The capacity of cancer cells to migrate is intimately linked to their ability to induce metastasis. Here the authors show that the sodium channel β4 subunit regulates breast cancer cell migration via inhibition of RhoA activation, independently from its function as an auxiliary protein of the sodium channel.

Published
2016

27. Serum Galectin-3 Levels Predict Recurrences after Ablation of Atrial Fibrillation

Author

Eric Piver, Laurent Fauchier, Anne Bernard, Dominique Babuty, Nazih Benhenda, Nicolas Clementy, Jean-Christophe Pages, Bertrand Pierre, Dorogoichenko, Aleksandra, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Morphogénèse et antigénicité du VIH et du virus des Hépatites (MAVIVH - U1259 Inserm - CHRU Tours ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Éducation Éthique Santé EA 7505 (EES), and Université de Tours (UT)

Subjects
0301 basic medicine, medicine.medical_specialty, medicine.medical_treatment, Ablation of atrial fibrillation, 030204 cardiovascular system & hematology, Article, [SHS]Humanities and Social Sciences, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Fibrosis, Left atrial, Internal medicine, medicine, [SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, cardiovascular diseases, Survival rate, Multidisciplinary, business.industry, Atrial fibrillation, Ablation, medicine.disease, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, 030104 developmental biology, Galectin-3, Cardiology, cardiovascular system, Biomarker (medicine), business
Abstract

Galectin-3 is a biomarker of fibrosis and atrial remodeling, involved in the mechanisms of initiation and maintenance of atrial fibrillation (AF). We sought to study the accuracy of galectin-3 level in predicting recurrences of AF after ablation. Serum concentrations of galectin-3 were determined in a consecutive series of patients addressed for AF ablation in our center. After a 3-month blanking period, recurrences of atrial arrhythmias were collected during the first year in all patients, using Holter monitoring at 3, 6 months and 12 months. A total of 160 patients were included, with a mean galectin-3 rate was 14.4 ± 5.6 ng/mL. At 12-month, 55 patients (34%) had reexperienced sustained atrial arrhythmia. Only higher galectin-3 level (HR = 1.07 [1.01–1.12], p = 0.02) and larger left atrial diameter (HR = 1.07 [1.03–1.12], p = 0.001) independently predicted recurrence. Patients with both galectin-3 level

Published
2016

28. Anti-Infectious Pathogen Specificity of Purified Monoclonal Immunoglobulins from Patients with MGUS and Multiple Myeloma

Author

Eric Piver, François Girodon, Jean-Christophe Pages, Edith Bigot-Corbel, Cathy Charlier, Delphine Feron, Sylvie Hermouet, Jean Harb, Adrien Bosseboeuf, Pierre Weigel, Laurent Garderet, Philippe Moreau, Cédric Rossi, Anne Tallet, Valéry Salle, Denis Caillot, Molecular Mechanisms of Chronic Inflammation in Hematological Diseases (CRCINA-ÉQUIPE 16), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Laboratoire de Biochimie [Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Unité de fonctionnalité et ingénierie de protéines (UFIP), Université de Nantes - UFR des Sciences et des Techniques (UN UFR ST), Université de Nantes (UN)-Université de Nantes (UN)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Service d'hématologie biologique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] (IBMM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre de ressources biologiques Ferdinand Cabanne [Dijon] (CRB Ferdinand Cabanne), Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hématologie Clinique (CHU de Dijon), Laboratoire d'Excellence : Lipoprotéines et Santé : prévention et Traitement des maladies Inflammatoires et du Cancer (LabEx LipSTIC), Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Gustave Roussy (IGR)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM)-Fédération Francophone de la Cancérologie Digestive, FFCD-Université de Montpellier (UM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), CHU Amiens-Picardie, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Unité de Biotechnologie, Biocatalyse et Biorégulation (U3B), Université de Nantes (UN)-Centre National de la Recherche Scientifique (CNRS), Etablissement Français du Sang, Haut Conseil des Biotechnologies (HCB), Université de Tours (UT), Laboratoire de Biochimie [CHRU Tours], Morphogénèse et antigénicité du VIH et du virus des Hépatites (MAVIVH - U1259 Inserm - CHRU Tours ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Service d'Hématologie [Nantes], Service d'hématologie biologique [CHU de Dijon], Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-École Pratique des Hautes Études (EPHE), and UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM)-Fédération Francophone de la Cancérologie Digestive, FFCD-Université de Montpellier (UM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC)

Subjects
Hepatitis C virus, [SDV]Life Sciences [q-bio], Immunology, Varicella zoster virus, Cell Biology, Hematology, Biology, medicine.disease, medicine.disease_cause, Biochemistry, Virology, Herpesviridae, Virus, Lymphoma, Antigen, hemic and lymphatic diseases, medicine, biology.protein, Antibody, Multiple myeloma
Abstract

Background: Multiple myeloma (MM) is characterized by the accumulation of malignant plasma cells, which secrete >30g/L of monoclonal immunoglobulin (mc Ig). MM is always preceded by the usually asymptomatic stage called "monoclonal gammapathy of undetermined significance" (MGUS). Presently the detection of a mc Ig does not lead to analysis of its specificity of antigen (Ag) recognition. Yet certain infectious pathogens are associated with the development of B-cell malignancy: for instance, Epstein-Barr virus (EBV) and Burkitt lymphoma, Helicobacter pylori (H. pylori) and MALT lymphoma. Objective: Our aim was to determine the frequency of recognition by purified mc Ig from MGUS and MM patients, of infectious pathogens associated with chronic infection and B-cell malignancy. Methods: We used the "Multiplex Infectious Antigen Array" (MIAA)test set up by the team to study the specificity of purified mc IgG against 8 infectious pathogens: hepatitis C virus (HCV), EBV, H. pylori, varicella zoster virus (VZV), cytomegalovirus (CMV), herpesvirus simplex 1 (HSV-1), HSV-2, and Toxoplasma gondii. Second or third methods were used to verify the specificity of mc IgG (western blotting, ELISA, or another multiplex array). Sialylation of mc Ig, which reflects chronic inflammation, was also studied, via ELISAs and Western blotting, for 98 MGUS and MM patients and 43 controls. Results: The specificity of purified mc IgG was analyzed for 291 patients (60 MGUS, including 4 associated with a B-cell lymphoma; 108 MM; for the 123 other patients the diagnosis of MGUS or MM was not available). Purified mc IgG were found to be specific for one of the 8 infectious pathogens of the MIAA test for 17.5% of patients (51/291: 25 MGUS, 1 SMM, and 25 MM). Purified mc Ig specifically recognized EBV (n=27, including 8 MGUS, 1 SMM and 18 MM ; the Ag recognized were EBNA-1, 25 cases; and VCA, 2 cases); HCV (10 cases: 9 MGUS and 1 MM) ; HSV-1 (7 cases: 5 MGUS including 3 associated with a B-cell malignancy, and 2 MM) ; H. pylori (5 cases: 2 MGUS including 1 associated with a B-cell malignancy, and 3 MM); VZV (1 MM); and CMV (1 MGUS). The Ag most frequently recognized by purified mc IgG was EBV EBNA-1; MM patients with EBNA-1-specific mc IgG represented 10% of the MM in this series. Consistent with a pro-inflammatory effect, for 81.6% of MGUS and MM patients (80/98), the purified mc IgG was found to be hyposialylated. Moreover, purified polyclonal Ig were also hyposialylated for 37% of MM (compared to Conclusion: At least 6 infectious pathogens (EBV, HCV, H. pylori, HSV, VZV, CMV) may be involved in the pathogenesis of MGUS and MM with mc IgG. Importantly, EBV, HCV, H. pylori and HSV are known as oncogenic pathogens associated with solid cancer and/or B-cell malignancy. Finally, for 37% of the MM patients examined, both the polyclonal and mc Ig were found to be hyposialylated, which suggests that inflammation existed prior to clonality and MM. Disclosures Garderet: Takeda: Consultancy; Amgen: Consultancy; BMS: Consultancy, Honoraria; Novartis: Consultancy.

Published
2016

29. Incomplete recovery of mechanical and endocrine left atrial functions one month after electrical cardioversion for persistent atrial fibrillation: a pilot study

Author

N. Zannad, Eric Piver, Laurent Fauchier, Dominique Babuty, Anne Bernard-Brunet, Jean-Christophe Pages, Christophe Saint Etienne, Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Virus, pseudo-virus: Morphogénèse et Antigénicité, Université de Tours (UT)-EA3856, Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Université de Tours (UT), Service de Cardiologie B, Éducation Éthique Santé EA 7505 (EES), Dorogoichenko, Aleksandra, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-CHU Trousseau [APHP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
Male, medicine.medical_specialty, medicine.medical_treatment, Electric Countershock, Endocrine System, Pilot Projects, Speckle tracking echocardiography, Cardioversion, General Biochemistry, Genetics and Molecular Biology, Electrical cardioversion, [SHS]Humanities and Social Sciences, Atrial natriuretic peptide, Internal medicine, medicine, Humans, Endocrine system, Sinus rhythm, Heart Atria, cardiovascular diseases, Prospective cohort study, Aged, Ultrasonography, Medicine(all), Ejection fraction, Biochemistry, Genetics and Molecular Biology(all), business.industry, Research, Speckle-tracking echocardiography, Atrial fibrillation, Recovery of Function, General Medicine, Left atrial remodeling, medicine.disease, Cardiology, cardiovascular system, Atrial Function, Left, Female, [SHS] Humanities and Social Sciences, business, Atrial Natriuretic Factor
Abstract

Background Restoration of the mechanical and endocrine functions of the left atrium remains controversial after electrical cardioversion treatment for persistent atrial fibrillation. The objective of the prospective study was to describe the recovery of the endocrine and mechanical functions of the left atrium. Methods Evaluation of left atrium recovery after electrical cardioversion by the new speckle-tracking echocardiography technique and proANP measurement. Results Twenty patients suffering from persistent atrial fibrillation with no alteration of left ventricular ejection fraction were prospectively evaluated at baseline and then one month later by echocardiography, measuring left atrial volume and left atrial deformation (MPALS), as well as the proANP and BNP concentrations. One month after cardioversion 10 patients remained in sinus rhythm and 10 showed recurrent atrial fibrillation. No significant differences between the two groups in terms of clinical, echocardiographic and endocrine parameters were observed at baseline evaluation. We observed a significant reduction of left atrial volume only in the sinus group, whereas restoration of the left atrial deformation was only partial (18%) in that group. By contrast, we registered no significant changes in ANP concentration at one month in either the sinus or the atrial fibrillation groups. Conclusion These results suggest that restoration of left atrium mechanical function is only partial one month after treatment of persistent atrial fibrillation by electrical cardioversion, whereas a significant reduction of left atrial volume was noted, explaining the remaining high level of ANP in the sinus group.

Published
2014

30. Viral sequence variation in chronic carriers of hepatitis C virus has a low impact on liver steatosis

Author

Yannick Bacq, Amélie Le Gouge, Eric Piver, Anne de Muret, Jean-Christophe Meunier, Marion Depla, Catherine Gaudy-Graffin, Farhad Kazemi, Aurélie Avargues, Christophe Hourioux, Philippe Roingeard, Julien Gaillard, Alain Moreau, Emmanuelle Roch, Bruno Giraudeau, and L. D’Alteroche

Subjects
Male, Viral Diseases, Hepacivirus, Biopsy, viruses, lcsh:Medicine, Viral Nonstructural Proteins, medicine.disease_cause, Hepatitis, 0302 clinical medicine, Lipid droplet, Genotype, lcsh:Science, Conserved Sequence, Phylogeny, 0303 health sciences, Multidisciplinary, biology, Viral Core Proteins, Liver Diseases, Fatty liver, Middle Aged, 3. Good health, Infectious Diseases, Liver, Host-Pathogen Interactions, Medicine, 030211 gastroenterology & hepatology, Female, Research Article, Adult, Hepatitis C virus, Molecular Sequence Data, Gastroenterology and Hepatology, Microbiology, Virus, 03 medical and health sciences, medicine, Humans, Amino Acid Sequence, NS5A, Biology, 030304 developmental biology, Aged, Infectious Hepatitis, lcsh:R, Genetic Variation, Hepatitis C, Chronic, biology.organism_classification, medicine.disease, Virology, Fatty Liver, Immunology, lcsh:Q, Steatosis
Abstract

Most clinical studies suggest that the prevalence and severity of liver steatosis are higher in patients infected with hepatitis C virus (HCV) genotype 3 than in patients infected with other genotypes. This may reflect the diversity and specific intrinsic properties of genotype 3 virus proteins. We analyzed the possible association of particular residues of the HCV core and NS5A proteins known to dysregulate lipid metabolism with steatosis severity in the livers of patients chronically infected with HCV. We used transmission electron microscopy to quantify liver steatosis precisely in a group of 27 patients, 12 of whom were infected with a genotype 3 virus, the other 15 being infected with viruses of other genotypes. We determined the area covered by lipid droplets in liver tissues and analyzed the diversity of the core and NS5A regions encoded by the viral variants circulating in these patients. The area covered by lipid droplets did not differ significantly between patients infected with genotype 3 viruses and those infected with other genotypes. The core and NS5A protein sequences of the viral variants circulating in patients with mild or severe steatosis were evenly distributed throughout the phylogenic trees established from all the collected sequences. Thus, individual host factors seem to play a much greater role than viral factors in the development of severe steatosis in patients chronically infected with HCV, including those infected with genotype 3 viruses.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results